DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
AZD-3759
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung
Epidermal growth factor receptor erbB1 inhibitor
AZD-3759
×
Maximum Phase:
2
First Approval:
None
UNII:
67SX9H68W2
Molecule Type:
Small molecule
Molecular Formula:
C22H23ClFN5O3
Molecular Weight:
459.91
AlogP:
4.31
PSA:
79.82
HBD:
1.0
HBA:
#RotB:
4.0
Source:
MIRAMISTIN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MIRAMISTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
QL5J8F55LH
Molecule Type:
Small molecule
Molecular Formula:
C26H47ClN2O
Molecular Weight:
439.13
AlogP:
6.47
PSA:
29.1
HBD:
1.0
HBA:
#RotB:
18.0
Source:
MIBAMPATOR
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Glutamate receptor ionotropic AMPA positive allosteric modulator
MIBAMPATOR
×
Maximum Phase:
2
First Approval:
None
UNII:
A9V5BW73UU
Molecule Type:
Small molecule
Molecular Formula:
C21H30N2O4S2
Molecular Weight:
438.62
AlogP:
2.88
PSA:
92.34
HBD:
2.0
HBA:
#RotB:
10.0
Source:
VIPIVOTIDE TETRAXETAN GALLIUM GA-68
2
Small molecule
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant
Unknown
VIPIVOTIDE TETRAXETAN GALLIUM GA-68
×
Maximum Phase:
2
First Approval:
None
UNII:
7P5C02S4X8
Molecule Type:
Small molecule
Molecular Formula:
C49H68GaN9O16
Molecular Weight:
1107.06
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
POLYDEXTROSE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
POLYDEXTROSE
×
Maximum Phase:
2
First Approval:
None
UNII:
VH2XOU12IE
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
WNT-974
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Squamous Cell
Probable protein-cysteine N-palmitoyltransferase porcupine inhibitor
WNT-974
×
Maximum Phase:
2
First Approval:
None
UNII:
U27F40013Q
Molecule Type:
Small molecule
Molecular Formula:
C23H20N6O
Molecular Weight:
396.45
AlogP:
3.79
PSA:
93.55
HBD:
1.0
HBA:
#RotB:
5.0
Source:
LY-2090314
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Pancreatic Neoplasms; Leukemia
Glycogen synthase kinase-3 alpha inhibitor
LY-2090314
×
Maximum Phase:
2
First Approval:
None
UNII:
822M3GYM67
Molecule Type:
Small molecule
Molecular Formula:
C28H25FN6O3
Molecular Weight:
512.55
AlogP:
3.42
PSA:
91.95
HBD:
1.0
HBA:
#RotB:
2.0
Source:
JNJ-41443532
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
C-C chemokine receptor type 2 antagonist
JNJ-41443532
×
Maximum Phase:
2
First Approval:
None
UNII:
0OJB0LES1A
Molecule Type:
Small molecule
Molecular Formula:
C22H25F3N4O3S
Molecular Weight:
482.53
AlogP:
2.52
PSA:
94.56
HBD:
3.0
HBA:
#RotB:
6.0
Source:
ORM-12741
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Alpha-2c adrenergic receptor antagonist
ORM-12741
×
Maximum Phase:
2
First Approval:
None
UNII:
D26C95A960
Molecule Type:
Small molecule
Molecular Formula:
C18H23NO2
Molecular Weight:
285.39
AlogP:
3.78
PSA:
25.61
HBD:
0.0
HBA:
#RotB:
2.0
Source:
PICTILISIB
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma, Non-Hodgkin; Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung
PI3-kinase class I inhibitor
PICTILISIB
×
Maximum Phase:
2
First Approval:
None
UNII:
ICY00EMP8P
Molecule Type:
Small molecule
Molecular Formula:
C23H27N7O3S2
Molecular Weight:
513.65
AlogP:
2.15
PSA:
107.55
HBD:
1.0
HBA:
#RotB:
5.0
Source:
DEXTOFISOPAM
2
Small molecule
Investigational
Unknown
Unknown
Irritable Bowel Syndrome
Unknown
DEXTOFISOPAM
×
Maximum Phase:
2
First Approval:
None
UNII:
EZ15I5D6C1
Molecule Type:
Small molecule
Molecular Formula:
C22H26N2O4
Molecular Weight:
382.46
AlogP:
4.44
PSA:
61.64
HBD:
0.0
HBA:
#RotB:
6.0
Source:
APILIMOD
2
Small molecule
Investigational
Unknown
Unknown
Common Variable Immunodeficiency; Crohn Disease; Severe Acute Respiratory Syndrome
1-phosphatidylinositol 3-phosphate 5-kinase inhibitor
APILIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
GFW2K84S4L
Molecule Type:
Small molecule
Molecular Formula:
C23H26N6O2
Molecular Weight:
418.5
AlogP:
3.08
PSA:
84.76
HBD:
1.0
HBA:
#RotB:
8.0
Source:
GW468816
2
Small molecule
Investigational
Unknown
Unknown
Tobacco Use Disorder
Glutamate [NMDA] receptor antagonist
GW468816
×
Maximum Phase:
2
First Approval:
None
UNII:
3WGI8FOO62
Molecule Type:
Small molecule
Molecular Formula:
C20H17ClN2O3
Molecular Weight:
368.82
AlogP:
3.8
PSA:
69.64
HBD:
2.0
HBA:
#RotB:
2.0
Source:
ME-401
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ME-401
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TIPEPIDINE
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity; Cough; Depressive Disorder
Unknown
TIPEPIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
2260ZP67IT
Molecule Type:
Small molecule
Molecular Formula:
C15H17NS2
Molecular Weight:
275.44
AlogP:
4.34
PSA:
3.24
HBD:
0.0
HBA:
#RotB:
2.0
Source:
INECALCITOL
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute
Vitamin D receptor agonist
INECALCITOL
×
Maximum Phase:
2
First Approval:
None
UNII:
05FZV98342
Molecule Type:
Small molecule
Molecular Formula:
C26H40O3
Molecular Weight:
400.6
AlogP:
4.76
PSA:
60.69
HBD:
3.0
HBA:
#RotB:
3.0
Source:
AZD5672
2
Small molecule
Investigational
Unknown
Unknown
Kidney Diseases; Arthritis, Rheumatoid
C-C chemokine receptor type 5 antagonist
AZD5672
×
Maximum Phase:
2
First Approval:
None
UNII:
61XQN688TW
Molecule Type:
Small molecule
Molecular Formula:
C31H43F2N3O5S2
Molecular Weight:
639.83
AlogP:
4.07
PSA:
95.07
HBD:
0.0
HBA:
#RotB:
11.0
Source:
ETHION
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ETHION
×
Maximum Phase:
2
First Approval:
None
UNII:
2TI07NO12Y
Molecule Type:
Small molecule
Molecular Formula:
C9H22O4P2S4
Molecular Weight:
384.49
AlogP:
5.01
PSA:
36.92
HBD:
0.0
HBA:
#RotB:
12.0
Source:
OC000459
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
OC000459
×
Maximum Phase:
2
First Approval:
None
UNII:
04XB9TB8OL
Molecule Type:
Small molecule
Molecular Formula:
C21H17FN2O2
Molecular Weight:
348.38
AlogP:
4.31
PSA:
55.12
HBD:
1.0
HBA:
#RotB:
4.0
Source:
GALUNISERTIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Paraganglioma; Triple Negative Breast Neoplasms; Carcinoma, Hepatocellular; Glioblastoma; Myelodysplastic Syndromes; Nasopharyngeal Carcinoma; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms
TGF-beta receptor type I inhibitor
GALUNISERTIB
×
Maximum Phase:
2
First Approval:
None
UNII:
3OKH1W5LZE
Molecule Type:
Small molecule
Molecular Formula:
C22H19N5O
Molecular Weight:
369.43
AlogP:
3.51
PSA:
86.69
HBD:
1.0
HBA:
#RotB:
3.0
Source:
OLEIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Multiple Sclerosis; Adenoma
Unknown
OLEIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
2UMI9U37CP
Molecule Type:
Small molecule
Molecular Formula:
C18H34O2
Molecular Weight:
282.47
AlogP:
6.11
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
15.0
Source:
R-406
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Tyrosine-protein kinase SYK inhibitor
R-406
×
Maximum Phase:
2
First Approval:
None
UNII:
RC3A285J2G
Molecule Type:
Small molecule
Molecular Formula:
C22H23FN6O5
Molecular Weight:
470.46
AlogP:
3.63
PSA:
128.75
HBD:
3.0
HBA:
#RotB:
7.0
Source:
SODIUM 2,2-DIMETHYLBUTYRATE
2
Small molecule
Investigational
Unknown
Unknown
Anemia, Sickle Cell; beta-Thalassemia
Unknown
SODIUM 2,2-DIMETHYLBUTYRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
XKM99SPB5I
Molecule Type:
Small molecule
Molecular Formula:
C6H11NaO2
Molecular Weight:
138.14
AlogP:
1.51
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
2.0
Source:
XBD173
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
XBD173
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
R-333
2
Small molecule
Investigational
Unknown
Unknown
Lupus Erythematosus, Systemic
Tyrosine-protein kinase JAK3 inhibitor
R-333
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SITAMAQUINE
2
Small molecule
Investigational
Unknown
Unknown
Leishmaniasis
Unknown
SITAMAQUINE
×
Maximum Phase:
2
First Approval:
None
UNII:
5AIJ4TGC6B
Molecule Type:
Small molecule
Molecular Formula:
C21H33N3O
Molecular Weight:
343.52
AlogP:
4.87
PSA:
37.39
HBD:
1.0
HBA:
#RotB:
11.0
Source:
TOLPERISONE
2
Small molecule
Investigational
Unknown
Unknown
Muscle Spasticity; Arthralgia; Low Back Pain; Myalgia
Unknown
TOLPERISONE
×
Maximum Phase:
2
First Approval:
None
UNII:
F5EOM0LD8E
Molecule Type:
Small molecule
Molecular Formula:
C16H23NO
Molecular Weight:
245.37
AlogP:
3.3
PSA:
20.31
HBD:
0.0
HBA:
#RotB:
4.0
Source:
ENRASENTAN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Endothelin receptor ET-A antagonist
ENRASENTAN
×
Maximum Phase:
2
First Approval:
None
UNII:
QG16H8A6ZH
Molecule Type:
Small molecule
Molecular Formula:
C29H30O8
Molecular Weight:
506.55
AlogP:
4.56
PSA:
103.68
HBD:
2.0
HBA:
#RotB:
10.0
Source:
DOCOSAPENTAENOIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Substance-Related Disorders
Unknown
DOCOSAPENTAENOIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
NS3OZT14QT
Molecule Type:
Small molecule
Molecular Formula:
C22H34O2
Molecular Weight:
330.51
AlogP:
6.77
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
15.0
Source:
CARICOTAMIDE
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular
Unknown
CARICOTAMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
MC09H30MFS
Molecule Type:
Small molecule
Molecular Formula:
C8H11N3O2
Molecular Weight:
181.19
AlogP:
-0.94
PSA:
89.42
HBD:
2.0
HBA:
#RotB:
3.0
Source:
BL-1020
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BL-1020
×
Maximum Phase:
2
First Approval:
None
UNII:
K1WO7H97QZ
Molecule Type:
Small molecule
Molecular Formula:
C25H34Cl2N4O2S
Molecular Weight:
525.55
AlogP:
4.23
PSA:
62.04
HBD:
1.0
HBA:
#RotB:
10.0
Source:
AEE-788
2
Small molecule
Investigational
Unknown
Unknown
Central Nervous System Neoplasms; Glioblastoma; Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
AEE-788
×
Maximum Phase:
2
First Approval:
None
UNII:
F9JLR95I3I
Molecule Type:
Small molecule
Molecular Formula:
C27H32N6
Molecular Weight:
440.6
AlogP:
4.94
PSA:
60.08
HBD:
2.0
HBA:
#RotB:
7.0
Source:
TEPILAMIDE FUMARATE
2
Small molecule
Investigational
Unknown
Unknown
Psoriasis
Unknown
TEPILAMIDE FUMARATE
×
Maximum Phase:
2
First Approval:
None
UNII:
KOS9TZ09CM
Molecule Type:
Small molecule
Molecular Formula:
C11H17NO5
Molecular Weight:
243.26
AlogP:
0.13
PSA:
72.91
HBD:
0.0
HBA:
#RotB:
6.0
Source:
IMD-1041
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor
IMD-1041
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SETOGEPRAM
2
Small molecule
Investigational
Unknown
Unknown
Hyperammonemia; Alstrom Syndrome
Free fatty acid receptor 1 agonist
SETOGEPRAM
×
Maximum Phase:
2
First Approval:
None
UNII:
879OVM0Y1S
Molecule Type:
Small molecule
Molecular Formula:
C13H18O2
Molecular Weight:
206.28
AlogP:
3.05
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
6.0
Source:
1
2
…
117
118
119
120
121
122
123
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA